Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04446117




Registration number
NCT04446117
Ethics application status
Date submitted
22/06/2020
Date registered
24/06/2020
Date last updated
23/05/2024

Titles & IDs
Public title
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
Scientific title
A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination With Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects With Metastatic Castration-Resistant Prostate Cancer
Secondary ID [1] 0 0
XL184-315
Universal Trial Number (UTN)
Trial acronym
CONTACT-02
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Metastatic Prostate Cancer 0 0
Prostate Adenocarcinoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Prostate

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Cabozantinib
Treatment: Drugs - Atezolizumab
Treatment: Drugs - Abiraterone Acetate
Treatment: Drugs - Enzalutamide
Treatment: Drugs - Prednisone

Experimental: Experimental Arm - Subjects with mCRPC will receive cabozantinib 40mg oral, qd + atezolizumab 1200mg infusion, q3w

Active Comparator: Control Arm - Subjects with mCRPC will receive active comparator of EITHER abiraterone 1000mg oral, qd + prednisone 5 mg oral, bid; OR enzalutamide 160mg oral, qd as designated by the Investigator prior to randomization


Treatment: Drugs: Cabozantinib
Supplied as 20-mg tablets; administered orally daily at 40mg

Treatment: Drugs: Atezolizumab
Supplied as 1200 mg/20 mL vials; administered as an IV infusion once every 3 weeks (q3w)

Treatment: Drugs: Abiraterone Acetate
Supplied as 500 mg tablets; administered orally daily at 1000mg with prednisone 5 mg orally bid

Treatment: Drugs: Enzalutamide
Supplied as 40 mg capsules; administered orally daily at 160mg

Treatment: Drugs: Prednisone
Supplied as 5 mg tablets; administered orally bid at 5 mg with abiraterone 1000mg orally daily
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Duration of Progression Free Survival per Response Evaluable Criteria in Solid Tumors version 1.1 (RECIST 1.1)
Timepoint [1] 0 0
Approximately 21 months after the first subject is randomized.
Primary outcome [2] 0 0
Duration of Overall Survival (OS)
Timepoint [2] 0 0
Approximately 37 months after the first subject is randomized
Secondary outcome [1] 0 0
Objective response rate (ORR)
Timepoint [1] 0 0
Approximately 37 months after the first subject is randomized

Eligibility
Key inclusion criteria
- Men with histologically or cytologically confirmed adenocarcinoma of the prostate

- Prior treatment with one, and only one, NHT (eg, abiraterone, apalutamide,
darolutamide, or enzalutamide) for castration-sensitive locally advanced (T3 or T4) or
mCSPC, M0 CRPC, or mCRPC

- Surgical or medical castration, with serum testosterone = 50 ng/dL (= 1.73 nmol/L) at
screening

- Measurable (extrapelvic soft tissue) metastatic disease per Investigator assessment
defined by at least one of the following: measurable visceral disease (eg, adrenal,
kidney, liver, lung, pancreas, spleen) per RECIST 1.1; OR measurable extrapelvic
adenopathy (ie, adenopathy above the aortic bifurcation)

- Progressive disease at study entry as defined by specific criteria for prostate
specific antigen (PSA) progression OR soft tissue disease progression in the opinion
of the Investigator (Note: subjects with bone disease progression alone are not
eligible)

- Age = 18 years old or meeting country definition of adult, whichever is older, on the
day of consent

- ECOG performance status of 0 or 1

- Recovery to baseline or = Grade 1 per Common Terminology Criteria for Adverse Events
(CTCAE) v5 from toxicities related to any prior treatments, unless AE(s) are
clinically nonsignificant and/or stable on supportive therapy in the opinion of the
Investigator

- Adequate organ and marrow function based upon specific laboratory assessments obtained
within 21 days prior to randomization

- Understanding and ability to comply with protocol requirements
Minimum age
18 Years
Maximum age
No limit
Sex
Males
Can healthy volunteers participate?
No
Key exclusion criteria
- Any prior nonhormonal therapy initiated for the treatment of mCRPC

- Receipt of abiraterone within 1 week; cyproterone within 10 days; or flutamide,
nilutamide, bicalutamide, enzalutamide, or other androgen-receptor inhibitors within 2
weeks before randomization

- Radiation therapy within 4 weeks (2 weeks for bone metastases) prior to randomization
(subjects with clinically relevant ongoing complications from prior radiation therapy
are not eligible)

- Known brain metastases or cranial epidural disease unless adequately treated and
clinically stable at least 4 weeks prior to randomization

- Symptomatic or impending spinal cord compression or cauda equina syndrome

- Concomitant anticoagulation with oral anticoagulants (some specific exceptions apply)

- Administration of a live, attenuated vaccine within 30 days prior to randomization

- Systematic treatment with, or any condition requiring, either corticosteroids (>10 mg
daily prednisone equivalent) or other immunosuppressive medications within 14 days
prior to randomization

- Uncontrolled, significant intercurrent or recent illness

- Major surgery within 4 weeks prior to randomization

- Corrected QT interval calculated by the Fridericia formula (QTcF) > 480 ms per ECG
within 21 days before randomization

- Inability or unwillingness to swallow pills or receive IV administration

- Previously identified allergy or hypersensitivity to components of the study treatment
formulations or history of severe infusion-related reactions to monoclonal antibodies

- Any other active malignancy at time of randomization or diagnosis of another
malignancy within 2 years prior to randomization that requires active treatment (some
exceptions apply such as locally curable cancers that have apparently been cured).

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
30/06/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
31/08/2024
Actual
Sample size
Target
Accrual to date
Final
575
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,TAS,VIC
Recruitment hospital [1] 0 0
Exelixis Clinical Site #151 - Garran
Recruitment hospital [2] 0 0
Exelixis Clinical Site #252 - Port Macquarie
Recruitment hospital [3] 0 0
Exelixis Clinical Site #175 - Saint Leonards
Recruitment hospital [4] 0 0
Exelixis Clinical Site # 189 - Sydney
Recruitment hospital [5] 0 0
Exelixis Site #162 - Wollongong
Recruitment hospital [6] 0 0
Exelixis Clinical Site #253 - Chermside
Recruitment hospital [7] 0 0
Exelixis Clinical Site #103 - Launceston
Recruitment hospital [8] 0 0
Exelixis Clinical Site #79 - Ballarat
Recruitment hospital [9] 0 0
Exelixis Clinical Site #95 - Frankston
Recruitment hospital [10] 0 0
Exelixis Clinical #262 - Geelong
Recruitment hospital [11] 0 0
Exelixis Clinical Site #53 - Melbourne
Recruitment hospital [12] 0 0
Exelixis Clinical Stie #260 - Saint Albans
Recruitment hospital [13] 0 0
Exelixis Clinical Site #115 - Adelaide
Recruitment hospital [14] 0 0
Exelixis Clinical Site #149 - Box Hill
Recruitment postcode(s) [1] 0 0
2605 - Garran
Recruitment postcode(s) [2] 0 0
2444 - Port Macquarie
Recruitment postcode(s) [3] 0 0
2065 - Saint Leonards
Recruitment postcode(s) [4] 0 0
2109 - Sydney
Recruitment postcode(s) [5] 0 0
2500 - Wollongong
Recruitment postcode(s) [6] 0 0
4032 - Chermside
Recruitment postcode(s) [7] 0 0
7250 - Launceston
Recruitment postcode(s) [8] 0 0
3350 - Ballarat
Recruitment postcode(s) [9] 0 0
3199 - Frankston
Recruitment postcode(s) [10] 0 0
3220 - Geelong
Recruitment postcode(s) [11] 0 0
3000 - Melbourne
Recruitment postcode(s) [12] 0 0
3021 - Saint Albans
Recruitment postcode(s) [13] 0 0
5000 - Adelaide
Recruitment postcode(s) [14] 0 0
3128 - Box Hill
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Kansas
Country [8] 0 0
United States of America
State/province [8] 0 0
Kentucky
Country [9] 0 0
United States of America
State/province [9] 0 0
Maryland
Country [10] 0 0
United States of America
State/province [10] 0 0
Michigan
Country [11] 0 0
United States of America
State/province [11] 0 0
Minnesota
Country [12] 0 0
United States of America
State/province [12] 0 0
Nebraska
Country [13] 0 0
United States of America
State/province [13] 0 0
Nevada
Country [14] 0 0
United States of America
State/province [14] 0 0
New Jersey
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
Ohio
Country [17] 0 0
United States of America
State/province [17] 0 0
Oklahoma
Country [18] 0 0
United States of America
State/province [18] 0 0
Pennsylvania
Country [19] 0 0
United States of America
State/province [19] 0 0
Tennessee
Country [20] 0 0
United States of America
State/province [20] 0 0
Texas
Country [21] 0 0
United States of America
State/province [21] 0 0
Utah
Country [22] 0 0
United States of America
State/province [22] 0 0
Virginia
Country [23] 0 0
Argentina
State/province [23] 0 0
Buenos Aires
Country [24] 0 0
Argentina
State/province [24] 0 0
Cordoba
Country [25] 0 0
Argentina
State/province [25] 0 0
Rio Negro
Country [26] 0 0
Argentina
State/province [26] 0 0
Santa Fe
Country [27] 0 0
Argentina
State/province [27] 0 0
Caba
Country [28] 0 0
Argentina
State/province [28] 0 0
Ciudad Autonoma de Buenos Aire
Country [29] 0 0
Argentina
State/province [29] 0 0
La Rioja
Country [30] 0 0
Argentina
State/province [30] 0 0
San Juan
Country [31] 0 0
Argentina
State/province [31] 0 0
San Salvador De Jujuy
Country [32] 0 0
Austria
State/province [32] 0 0
Oberösterreich
Country [33] 0 0
Austria
State/province [33] 0 0
Wien
Country [34] 0 0
Belgium
State/province [34] 0 0
Antwerpen
Country [35] 0 0
Belgium
State/province [35] 0 0
Oost-Vlaanderen
Country [36] 0 0
Belgium
State/province [36] 0 0
Brussels
Country [37] 0 0
Belgium
State/province [37] 0 0
Roeselare
Country [38] 0 0
Brazil
State/province [38] 0 0
Parana
Country [39] 0 0
Brazil
State/province [39] 0 0
Paraná
Country [40] 0 0
Brazil
State/province [40] 0 0
Rio Grande Do Sul
Country [41] 0 0
Brazil
State/province [41] 0 0
RJ
Country [42] 0 0
Brazil
State/province [42] 0 0
Santa Catarina
Country [43] 0 0
Brazil
State/province [43] 0 0
Sao Paulo
Country [44] 0 0
Brazil
State/province [44] 0 0
SP
Country [45] 0 0
Brazil
State/province [45] 0 0
São Paulo
Country [46] 0 0
Brazil
State/province [46] 0 0
Barretos
Country [47] 0 0
Brazil
State/province [47] 0 0
Fortaleza
Country [48] 0 0
Brazil
State/province [48] 0 0
Porto Alegre
Country [49] 0 0
Brazil
State/province [49] 0 0
Ribeirão Preto
Country [50] 0 0
Brazil
State/province [50] 0 0
Santa Cruz Do Sul
Country [51] 0 0
Canada
State/province [51] 0 0
Alberta
Country [52] 0 0
Canada
State/province [52] 0 0
British Columbia
Country [53] 0 0
Canada
State/province [53] 0 0
New Brunswick
Country [54] 0 0
Canada
State/province [54] 0 0
Ontario
Country [55] 0 0
Canada
State/province [55] 0 0
Quebec
Country [56] 0 0
Chile
State/province [56] 0 0
Región De Valparaíso
Country [57] 0 0
Chile
State/province [57] 0 0
Región Metropolitana De Santiago
Country [58] 0 0
Chile
State/province [58] 0 0
Región Metropolitana
Country [59] 0 0
Chile
State/province [59] 0 0
Providencia
Country [60] 0 0
Chile
State/province [60] 0 0
Recoleta
Country [61] 0 0
Chile
State/province [61] 0 0
Santiago
Country [62] 0 0
Chile
State/province [62] 0 0
Temuco
Country [63] 0 0
Chile
State/province [63] 0 0
Valparaíso
Country [64] 0 0
Czechia
State/province [64] 0 0
Praha
Country [65] 0 0
Czechia
State/province [65] 0 0
Brno
Country [66] 0 0
Czechia
State/province [66] 0 0
Olomouc
Country [67] 0 0
Czechia
State/province [67] 0 0
Praha 2
Country [68] 0 0
Czechia
State/province [68] 0 0
Praha 8
Country [69] 0 0
France
State/province [69] 0 0
Brest
Country [70] 0 0
France
State/province [70] 0 0
Clermont-Ferrand
Country [71] 0 0
France
State/province [71] 0 0
Dijon cedex
Country [72] 0 0
France
State/province [72] 0 0
Hyères
Country [73] 0 0
France
State/province [73] 0 0
La Roche-sur-Yon Cedex 9
Country [74] 0 0
France
State/province [74] 0 0
Nîmes
Country [75] 0 0
France
State/province [75] 0 0
Paris
Country [76] 0 0
France
State/province [76] 0 0
Quimper
Country [77] 0 0
France
State/province [77] 0 0
Reims
Country [78] 0 0
France
State/province [78] 0 0
Saint-Grégoire
Country [79] 0 0
France
State/province [79] 0 0
Strasbourg
Country [80] 0 0
France
State/province [80] 0 0
Toulouse
Country [81] 0 0
France
State/province [81] 0 0
Vandoeuvre les nancy
Country [82] 0 0
Georgia
State/province [82] 0 0
Tbilisi
Country [83] 0 0
Germany
State/province [83] 0 0
Baden-Wuerttemberg
Country [84] 0 0
Germany
State/province [84] 0 0
Nordrhein-Westfalen
Country [85] 0 0
Germany
State/province [85] 0 0
North Rhine-Westphalia
Country [86] 0 0
Germany
State/province [86] 0 0
Schleswig-Holstein
Country [87] 0 0
Germany
State/province [87] 0 0
Berlin
Country [88] 0 0
Germany
State/province [88] 0 0
Hamburg
Country [89] 0 0
Germany
State/province [89] 0 0
Hannover
Country [90] 0 0
Germany
State/province [90] 0 0
Tübingen
Country [91] 0 0
Greece
State/province [91] 0 0
Attica
Country [92] 0 0
Greece
State/province [92] 0 0
Crete
Country [93] 0 0
Greece
State/province [93] 0 0
Macedonia
Country [94] 0 0
Greece
State/province [94] 0 0
Thessaly
Country [95] 0 0
Hungary
State/province [95] 0 0
Budapest
Country [96] 0 0
Hungary
State/province [96] 0 0
Debrecen
Country [97] 0 0
Hungary
State/province [97] 0 0
Gyula
Country [98] 0 0
Israel
State/province [98] 0 0
Haifa
Country [99] 0 0
Israel
State/province [99] 0 0
Jerusalem
Country [100] 0 0
Israel
State/province [100] 0 0
Petah tikva
Country [101] 0 0
Israel
State/province [101] 0 0
Ramat Gan
Country [102] 0 0
Israel
State/province [102] 0 0
Safed
Country [103] 0 0
Israel
State/province [103] 0 0
Tel Aviv
Country [104] 0 0
Italy
State/province [104] 0 0
FC
Country [105] 0 0
Italy
State/province [105] 0 0
Milano
Country [106] 0 0
Italy
State/province [106] 0 0
SO
Country [107] 0 0
Italy
State/province [107] 0 0
Trentino
Country [108] 0 0
Italy
State/province [108] 0 0
Ancona
Country [109] 0 0
Italy
State/province [109] 0 0
Firenze
Country [110] 0 0
Italy
State/province [110] 0 0
Milan
Country [111] 0 0
Italy
State/province [111] 0 0
Parma
Country [112] 0 0
Italy
State/province [112] 0 0
Pavia
Country [113] 0 0
Italy
State/province [113] 0 0
Perugia
Country [114] 0 0
Italy
State/province [114] 0 0
Pisa
Country [115] 0 0
Italy
State/province [115] 0 0
Roma
Country [116] 0 0
Italy
State/province [116] 0 0
Terni
Country [117] 0 0
Japan
State/province [117] 0 0
Aichi
Country [118] 0 0
Japan
State/province [118] 0 0
Akita
Country [119] 0 0
Japan
State/province [119] 0 0
Aomori
Country [120] 0 0
Japan
State/province [120] 0 0
Chiba
Country [121] 0 0
Japan
State/province [121] 0 0
Hokkaido
Country [122] 0 0
Japan
State/province [122] 0 0
Hyogo
Country [123] 0 0
Japan
State/province [123] 0 0
Kagawa
Country [124] 0 0
Japan
State/province [124] 0 0
Kanagawa
Country [125] 0 0
Japan
State/province [125] 0 0
Miyagi
Country [126] 0 0
Japan
State/province [126] 0 0
Osaka-shi
Country [127] 0 0
Japan
State/province [127] 0 0
Saitama
Country [128] 0 0
Japan
State/province [128] 0 0
Shizuoka
Country [129] 0 0
Japan
State/province [129] 0 0
Tokyo
Country [130] 0 0
Japan
State/province [130] 0 0
Yamaguchi
Country [131] 0 0
Japan
State/province [131] 0 0
Fukuoka
Country [132] 0 0
Japan
State/province [132] 0 0
Nagano
Country [133] 0 0
Japan
State/province [133] 0 0
Wakayama
Country [134] 0 0
Japan
State/province [134] 0 0
Osaka-sayama
Country [135] 0 0
Korea, Republic of
State/province [135] 0 0
Daejeon
Country [136] 0 0
Korea, Republic of
State/province [136] 0 0
Gyeonggi-do
Country [137] 0 0
Korea, Republic of
State/province [137] 0 0
Gyeonggi-Do
Country [138] 0 0
Korea, Republic of
State/province [138] 0 0
Jeollanam-do
Country [139] 0 0
Korea, Republic of
State/province [139] 0 0
Busan
Country [140] 0 0
Korea, Republic of
State/province [140] 0 0
Daegu
Country [141] 0 0
Korea, Republic of
State/province [141] 0 0
Gwangju
Country [142] 0 0
Korea, Republic of
State/province [142] 0 0
Seoul
Country [143] 0 0
Mexico
State/province [143] 0 0
Chiapas
Country [144] 0 0
Mexico
State/province [144] 0 0
Distrito Federal
Country [145] 0 0
Mexico
State/province [145] 0 0
Guanajuato
Country [146] 0 0
Mexico
State/province [146] 0 0
Jalisco
Country [147] 0 0
Mexico
State/province [147] 0 0
Nuevo Leon
Country [148] 0 0
Mexico
State/province [148] 0 0
Queretaro
Country [149] 0 0
Mexico
State/province [149] 0 0
San Luis Potosi
Country [150] 0 0
Mexico
State/province [150] 0 0
Sinaloa
Country [151] 0 0
Mexico
State/province [151] 0 0
Mexico City
Country [152] 0 0
Mexico
State/province [152] 0 0
Puebla
Country [153] 0 0
Poland
State/province [153] 0 0
Mazowieckie
Country [154] 0 0
Poland
State/province [154] 0 0
Bydgoszcz
Country [155] 0 0
Poland
State/province [155] 0 0
Poznan
Country [156] 0 0
Poland
State/province [156] 0 0
Lódz
Country [157] 0 0
Portugal
State/province [157] 0 0
Braga
Country [158] 0 0
Portugal
State/province [158] 0 0
Guimarães
Country [159] 0 0
Portugal
State/province [159] 0 0
Lisboa
Country [160] 0 0
Portugal
State/province [160] 0 0
Loures
Country [161] 0 0
Portugal
State/province [161] 0 0
Porto
Country [162] 0 0
Portugal
State/province [162] 0 0
Vila Real
Country [163] 0 0
Russian Federation
State/province [163] 0 0
Moscow
Country [164] 0 0
Russian Federation
State/province [164] 0 0
Saint Petersburg
Country [165] 0 0
Singapore
State/province [165] 0 0
Singapore
Country [166] 0 0
Spain
State/province [166] 0 0
Alicante
Country [167] 0 0
Spain
State/province [167] 0 0
Asturias
Country [168] 0 0
Spain
State/province [168] 0 0
Barcelona
Country [169] 0 0
Spain
State/province [169] 0 0
Islas Baleares
Country [170] 0 0
Spain
State/province [170] 0 0
La Coruna
Country [171] 0 0
Spain
State/province [171] 0 0
Madrid
Country [172] 0 0
Spain
State/province [172] 0 0
Badalona
Country [173] 0 0
Spain
State/province [173] 0 0
Cadiz
Country [174] 0 0
Spain
State/province [174] 0 0
Córdoba
Country [175] 0 0
Spain
State/province [175] 0 0
Lugo
Country [176] 0 0
Spain
State/province [176] 0 0
Málaga
Country [177] 0 0
Spain
State/province [177] 0 0
Sevilla
Country [178] 0 0
Taiwan
State/province [178] 0 0
Kaohsiung
Country [179] 0 0
Taiwan
State/province [179] 0 0
Taichung City
Country [180] 0 0
Taiwan
State/province [180] 0 0
Taichung
Country [181] 0 0
Taiwan
State/province [181] 0 0
Tainan City
Country [182] 0 0
Taiwan
State/province [182] 0 0
Tainan
Country [183] 0 0
Taiwan
State/province [183] 0 0
Taipei city
Country [184] 0 0
Taiwan
State/province [184] 0 0
Taoyuan
Country [185] 0 0
Ukraine
State/province [185] 0 0
Dnipro
Country [186] 0 0
Ukraine
State/province [186] 0 0
Kyiv
Country [187] 0 0
Ukraine
State/province [187] 0 0
Luts'k
Country [188] 0 0
United Kingdom
State/province [188] 0 0
England
Country [189] 0 0
United Kingdom
State/province [189] 0 0
Lancashire
Country [190] 0 0
United Kingdom
State/province [190] 0 0
Middlesex
Country [191] 0 0
United Kingdom
State/province [191] 0 0
Wales

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Exelixis
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Roche-Genentech
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Commercial sector/Industry
Name [2] 0 0
Takeda
Address [2] 0 0
Country [2] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This is a Phase 3, multi-center, randomized, open-label, controlled study designed to
evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab
versus a second novel hormonal therapy (NHT) in men with metastatic castration-resistant
prostate cancer (mCRPC) who have previously been treated with one, and only one, NHT for
their prostate cancer disease.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04446117
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries